Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...

Oppenheimer initiated coverage of Compugen (CGEN) with an Outperform rating and $4 price target. With a sole oncology focus, Compugen is ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Regeneron (REGN – Research Report), with a price target ...

Gilead Sciences' chief medical officer ... years for the company as we worked to strengthen and diversify the portfolio." He added: "We have more than doubled our portfolio under Merdad's ...

AZ was the driving force behind that potential deal, and the appeal of adding Gilead’s portfolio to its own was based on Gilead’s work to build its HIV business. The therapeutic area has ...

Wells Fargo's profit climbed in the fourth quarter, buoyed by stronger investment banking earnings, it said on Wednesday.

Heading into the end of the year, the investment market has given us and our clients plenty to be thankful for Even so, more ...